Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients

The University of Hong Kong (HKU)

Status: Enrolling

Conditions: Hepatorenal Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT02434445

UW12342

Details and patient eligibility

About

This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.

Full description

This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers tested include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation
• Willing to give informed consent

Exclusion criteria

• Patients with co-existing renal diseases

Trial design

100 participants in 2 patient groups

Hepatorenal syndrome group

Description:

Patients with advanced cirrhosis who develope hepatorenal syndrome

Non-hepatorenal syndrome group

Description:

Patients with advanced cirrhosis who do not hepatorenal syndrome